Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically proven NSCLC patients * All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest CT and PET-CT * 18 year of ages or older * ECOG performance status 0-1 * Uni-dimensionally measurable lesion by RECIST criteria * No prior chemotherapy or radiotherapy for NSCLC * Pre-operative FEV1 ≥ 2.0 L evaluated within 28 days * Adequate bone marrow function: Hb \> 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥ 100,000/μL * Adequate liver and renal function: Total bilirubin \< 2 x ULN, AST/ALT \< 3 x ULN, serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min * Written informed consent Exclusion Criteria: * Superior sulcus tumor * Prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years * Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia * Recent myocardial infarction within 6 months * Patients with post-obstructive pneumonia or serious infection * Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method.) * Patients with psychological problem